Net Loss Per Share

9 Months Ended

Sep. 30, 2020

Basic and diluted net loss per share attributable to common shareholders of Biohaven Pharmaceutical Holding Company Ltd. was calculated as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
Numerator:
Net loss	$	(196,628)	$	(106,167)	$	(550,499)	$	(379,541)
Net income (loss) attributable to non-controlling interests	(1,439)		—		(1,439)		—

Net loss attributable to common shareholders of Biohaven Pharmaceutical Holding Company Ltd.	$	(195,189)	$	(106,167)	$	(549,060)	$	(379,541)
Denominator:
Weighted average common shares outstanding—basic and diluted	59,677,989		52,077,240		58,282,697		47,210,615
Net loss per share attributable to common shareholders of Biohaven Pharmaceutical Holding Company Ltd.—basic and diluted	$	(3.27)	$	(2.04)	$	(9.42)	$	(8.04)

The Company’s potential dilutive securities, which include stock options, restricted share units, and warrants to purchase common shares, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common shareholders of the Company is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common shareholders for the periods indicated because including them would have had an anti-dilutive effect:


	As of September 30,
		2020	2019
Options to purchase common shares		7,946,120	8,560,514
Warrants to purchase common shares		106,751	106,751
Restricted share units		486,260	—
		8,539,131	8,667,265